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Abstract: 
The United Nations and the World Health Organization have designated antimicrobial resistance (AMR) 
as a major health priority and developed action plans to reduce AMR in all healthcare settings. 
Establishment of institutional antimicrobial stewardship programmes (ASPs) is advocated as a key 
intervention to reduce antibiotic consumption in hospitals and address high rates of multi-drug resistant 
(MDR) bacteria. We searched PUBMED and the Cochrane database of systematic reviews (1/2007-
3/2017) to identify studies reporting about the effectiveness of ASPs in general paediatric wards and 
paediatric intensive care units (PICU), on reducing antibiotic consumption, on using broad 
spectrum/restricted antibiotics, and on antibiotic resistance and healthcare-associated infections (HAIs). 
Neonatal units and antifungal agents were excluded. Of 2509 titles and abstracts, nine articles were 
eligible to be included in the final analysis. All studies reported on the reduction of broad 
spectrum/restricted antibiotics or antibiotic consumption.  One study reported on the reduction of HAI 
in a PICU, and another evaluated bacterial resistance, showing no effect following ASP implementation. 
Prospective audit on antibiotic use was the most common ASP core component (eight of nine studies). 
Antibiotic pre-authorisation was described in two articles. Other described interventions were providing 
guidelines or written information (five of nine articles), and training of healthcare professionals (one 
article). There is limited evidence about reducing antibiotic consumption and broad-spectrum/restricted 
agents following ASP implementation, specifically in PICU. Data evaluating the impact of ASPs on HAI 
and AMR in PICU is lacking. In addition, there is limited information on effective components of a 
successful ASPs in PICUs.  
 
Key words: antimicrobial stewardship programme, PICU, multi-drug resistant bacteria, MDRO, children. 
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Introduction 
Infectious diseases remain the most common indication for hospitalisation in paediatric wards and 
paediatric intensive care units (PICUs) worldwide. 
1
 Antibiotic use in paediatric inpatient settings was 
reported at 37% in a recent global point prevalence survey, with the highest antimicrobial use (61%) 
seen in PICU. 
2
 Although viral pathogens are a frequent cause of infection in paediatric populations, 
antibiotics are frequently inappropriately administered, owing to parental demand or physician 
uncertainty of the causative pathogen. 
3  
Large-scale misuse of antibiotics in healthcare settings worldwide, both for community-acquired and 
healthcare-associated infections (HAIs) has contributed to the emergence of multi-drug resistant (MDR) 
bacteria, with increasingly limited therapeutic options. 
4
 The problem of antimicrobial resistance (AMR) 
was recognized by the World Health Organization (WHO) and the United Nations (UN) at the General 
Assembly of 2016. 
5,6
 Five key strategies to tackle AMR were defined including: understanding of AMR 
through effective communication, education and training, development of new drugs and diagnostic 
tools, and development of the economic case for sustainable investment that takes account of the 
needs of all countries. 
6 
One strategy used to combat AMR is the development of country-level and institutional antimicrobial 
stewardship programmes (ASPs). The aim of this strategy is to analyse patterns of antibiotic use and 
identify local interventions to rationalize antibiotic therapy. The Infectious Disease Society of America 
(IDSA), defines ASP as "a set of coordinated interventions, designed to improve and measure the 
appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen 
(including the appropriate agent, dose, route of administration, and duration of therapy)". 
7 
In critical care units such as PICU, where broad-spectrum antibiotic use is common, as well the presence 
of MDR bacteria and HAI; adequate monitoring of antibiotic use and improvement of rational antibiotic 
use are necessary. The introduction of institutional ASPs could contribute to patient safety in this 
population. Prospective audits with immediate feedback, formulary restriction, and pre-authorisation 
(also referred to as prior approval) influenced antibiotic use in a recent pilot study.
8
 Based on the 
findings, the authors concluded that cost savings can be estimated at more than 330,000 € per year, and 
reduction would include broad-spectrum antibiotics and antifungals. 
8 
 
The aim of this systematic review was to identify studies reporting on the effectiveness of ASPs in 
reducing antibiotic consumption/use of (broad-spectrum) antibiotics, reducing antibiotic resistance, and 
preventing HAI in children, including PICU settings. In addition, components of ASPs were to be 
described. 
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Materials and methods: 
This systematic review was conducted according to the PRISMA guidelines. 
9  
 
Search strategy:  
We searched for publications in PUBMED and the Cochrane database of systematic reviews (from 1 
January 2007 to 31 March 2017) using the search term “antimicrobial stewardship”, limiting age 
(children from birth to less than 18 years), but without language restrictions.  
 
Eligibility criteria 
Inclusion criteria  
Setting: Studies were eligible for full text review if they were conducted in children hospitalized in an 
acute care setting, including PICUs. Eligible study designs included quantitative studies, such as 
randomised controlled trials, controlled and non-controlled before-and-after studies, controlled and 
non-controlled interrupted time series, and cohort studies.  
Exclusion criteria 
Review articles, case series, letters, notes, conference abstracts, and opinion articles were excluded. 
Interventions in outpatient care, neonatal units, emergency departments, long-term care facilities, or a 
combination of such settings were also excluded, as well as quantitative or qualitative studies 
addressing ASPs in both adults and children (where extraction of paediatric data was not possible). 
Studies focusing on antifungal agents were also excluded. 
  
Study selection:  
Title and abstract sift as well as full text assessment was conducted independently by three investigators 
(ARAS, AFM and CBB); any differences in opinion regarding inclusion criteria were resolved by group 
discussion. Three rounds of article assessment were conducted before selecting the final list for data 
abstraction: 
a) First-round: Exclusion of duplicate articles.  
b) Second-round: Title and abstract sift.  
c) Third round: Full text assessment.  
After the third round, relevant papers cited as references of full text articles were included for analysis, 
if they fulfilled the eligibility criteria. 
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Data collection 
Data were extracted using a standardized data-extraction form, which summarized the study details 
including authors, year of publication, country or countries where the study was performed, time frame 
of the study, and patient population (infant or early childhood, children, or adolescents). 
 
 Quality of articles and risk of bias  
Quality of articles was assessed using the integrated quality criteria for systematic review of multiple 
study designs (ICROMS) tool. 
10
 In summary the tool consists of two parts: the first is a list of quality 
criteria specific for each study design, as well as criteria applicable across all study designs by using a 
scoring system, and the second is a ‘decision matrix’, which specifies the robustness of the study by 
identifying minimum requirements according to the study type and the relevance of the study to the 
review question. Only studies meeting the minimum score and the mandatory criteria, according the 
ICROMS methodology, were included for the final analysis and data abstraction. (Annex 1)  
 
Analysis of antibiotic stewardship components (interventions) of identified articles  
ASP was defined according to the IDSA and the Society for Healthcare Epidemiology of America (SHEA) 
with the following core components: prospective audit and feedback, formulary restriction, and pre-
authorisation. 
7
 We also assessed the following components: use of guidelines or written information, 
and training of paediatric staff. 
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Results: 
Of 2509 titles and abstracts, nine articles were eligible to be included in the final analysis (Figure 1). Six 
of the nine publications originated from the USA, one from Germany, one from Singapore, and one from 
Indonesia.  
Three studies used a non-controlled before-and-after design, two were controlled interrupted series 
studies, two were non-controlled interrupted series, one was a cohort study, and one was a controlled 
before-and-after study. All studies included in final analysis met both mandatory criteria and the 
minimum score according the ICRMOS methodology. Study design, setting, number of subjects, country, 
study period, aims, interventions, and summary of key findings of the final articles are summarised in 
table 1.  
Eight of the nine studies applied a multi-modal or multifaceted intervention, combining two or more 
components simultaneously. Five studies reported on the reduction of antibiotic consumption 
11-15
, 
seven reported on the reduction of broad spectrum/restricted antibiotic use 
11,12,15-19
, one reported on 
HAI reduction , 
13
  and one reported on reduction of bacterial resistance.
18
 Two studies evaluated ASPs 
costs. 
14,16
 Eight of the nine studies reported statistically significant antibiotic reduction (either for all 
and/or for restricted antibiotics). 
11-15, 17-19
  
Prospective audit was one of the core components in eight studies. 
11, 13-19
 Antibiotic pre-authorisation 
was one of the core components in two studies.
16,18
 Other core components included use of guidelines 
or written information (five studies), 
11, 13, 14,17,19 
and training of healthcare professionals (one study).
13
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Discussion: 
One strategy to improve and rationalize the use of antibiotics is the adoption of an ASP. These 
programmes usually combine several measures to encourage rational antibiotic use both for inpatient 
and outpatient settings, and for all patient groups (adults, children, infants, neonates). ASP may have an 
important contribution to rationalizing antibiotic use in critically-ill children in PICUs, where the 
combination of AMR and  high rates of invasive device use put patients at risk for HAI due to MDR 
pathogens.
20
 In addition to tackle inappropriate antibiotic use, there is an urgency to conduct research 
on new antibiotics/antibiotic classes for critical MDR pathogens such as carbapenem-resistant 
Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant 
Enterobacteriaceae, and extended spectrum beta-lactamase (ESBL)-producing enterobacteriaceae. 
21,22 
It is plausible to assume that reducing antibiotic use would also reduce AMR in paediatric hospitals. A 
recent systematic review reported about the benefits of ASPs in reducing the incidence of infections and 
colonization with antibiotic-resistant bacteria and Clostridium difficile infections in adults. 
23 
However, 
other factors such as environmental control, outbreak management, isolation precaution measures, and 
hand hygiene contribute to the control of emerging resistance as well. 
The most important difference between ASPs for children and ASPs for adults is outcome measurement: 
antibiotic dosage in children is based on body weight or body surface, and thus, defined daily dose 
(DDD) as the preferred measurement of antibiotic consumption is not applicable.  
24
 One alternative to 
measure antimicrobial use is days of therapy (as per 1000 patient-days).
11,14,15
 Unfortunately, such data 
cannot be compared to DDDs from adults. 
Eight articles of our systematic review came from high-income countries (six from the same country).  
Only one study was done in a low-middle-income country. 
25
 No articles from low-income countries 
were identified. This is very concerning because emerging resistance, particularly for Gram-negative 
microorganisms, appears to be alarming in countries with limited resources, and knowledge about how 
to introduce effective ASP in these setting is urgently required.
26, 27 
Although ASPs were effective in reducing antibiotic consumption for both all antibiotic use and selected 
antibiotic use in (general) paediatric wards, no effect was found in PICUs. No study was sufficiently 
powered to demonstrate any impact on AMR or HAI.      
An important aspect of ASPs for hospitalised children, is training of healthcare professionals. We found 
this component only in one study. 
13
 From our point of view, continuous education and training of 
healthcare professionals on appropriate antibiotic use is essential. Local antibiotic resistance and case-
mix must be taken into account to help clinicians making rational choices on antibiotic use. 
This review highlights the difficulties in implementing and sustaining ASPs in PICUs, where critically-ill 
children frequently receive broad-spectrum antibiotic therapy to empirically cover MDR pathogens 
encountered particularly in HAI. Disease severity in PICUs may not allow to use narrow spectrum 
antibiotics empirically, but important aspects of ASPs in critical care include rapid identification of 
bacterial infections (if possible with rapid testing) to narrow treatment as soon as possible, and 
shortening the duration of antibiotic therapy by using ancillary tests. 
28
 These strategies allow the 
reduction of antibiotic exposure overall and avoiding the inappropriate use of broad-spectrum 
antibiotics while providing optimal care. 
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Our systematic review has some limitations. First, only two databases were searched and some 
potentially eligible studies might have been missed. Second, we only included reports from the past 10 
years (from 1/2007 to 3/2017). Although inappropriate use of antibiotics in hospitals is not a recent 
problem, ASP as a strategy was rarely addressed before the introduction of the IDSA guideline on ASP in 
2007.
7
 Bias of articles included in final analysis were minimized by using ICRMOS methodology, which 
identified papers with mandatory requests and minimum criteria for inclusion.  
This review provides a model for the implementation of ASPs in PICU and broader strategies to reduce 
antibiotic resistance.  Implementation research on how to most effectively introduce ASPs in paediatric 
hospitals is needed, particularly from low- and middle-income countries where options for therapy of 
MDR infection are extremely limited.  
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Table 1 - Quality criteria for application per study design- Integrated quality criteria for review of multiple study designs (ICROMS) 
Quality criteria Study design 
b
 
Dimension Specific criteria 
a
 RCT CBA CITS NCITS NCBA CS QUAL 
1. Clear aims and justification a. Clear statement of the aims of research? 
b. Rationale for number of pre-and post-intervention points or adequate baseline 
measurement 
c. Explanation for lack of control group 
d. Appropriateness of qualitative methodology 
e. Appropriate study design 
++ 
x 
 
x 
x 
x 
++ 
x 
 
x 
x 
x 
++ 
+ 
 
x 
x 
x 
++ 
++ 
 
+ 
x 
x 
++ 
++ 
 
+ 
x 
x 
++ 
x 
 
x 
x 
x 
++ 
x 
 
x 
+ 
++ 
2. Managing bias in sampling or 
between groups 
a. Sequence generation 
b. Allocation concealment 
c. Justification for sample choice 
d. Intervention and control group selection designed to protect against systematic 
difference/selection bias 
e. Comparability of groups 
f. Sampling and recruitment 
++ 
++ 
x 
x 
 
x 
x 
x 
x 
x 
++ 
 
x 
x 
x 
x 
x 
x 
 
x 
x 
x 
x 
++ 
x 
 
x 
x 
x 
x 
++ 
x 
 
x 
x 
x 
x 
x 
x 
 
++ 
x 
x 
x 
x 
x 
 
x 
++ 
3. Managing bias in outcome 
measurements and blinding 
a. Blinding 
b. Baseline measurement- protection against selection bias 
c. Protection against contamination 
d. Protection against secular changes 
e. Protection against detection bias: blinded assessment of primary outcome 
measures 
f. Reliable primary outcome measures 
g. Comparability of outcomes 
++ 
x 
x 
x 
+ 
 
+ 
x 
x 
++ 
++ 
x 
+ 
 
+ 
x 
x 
x 
x 
++ 
+ 
 
+ 
x 
x 
x 
x 
x 
+ 
 
+ 
x 
x 
x 
x 
x 
+ 
 
+ 
x 
x 
x 
x 
x 
+ 
 
+ 
++ 
x 
x 
x 
x 
x 
 
+ 
x 
4. Managing bias in follow-up a. Follow-up of subjects (protection against exclusion bias) 
b. Follow-up of patients of episodes of care 
c. Incomplete outcome data addressed 
+ 
+ 
+ 
x 
x 
+ 
x 
x 
+ 
x 
x 
+ 
x 
x 
+ 
x 
x 
++ 
x 
x 
+ 
5. Managing bias in other study aspects a. Protection against detection bias: intervention unlikely to affect data collection 
b. Protection against information bias 
c. Data collection appropriate to address research aims 
d. Attempts to mitigate effects of no control 
+ 
x 
x 
x 
+ 
x 
x 
x 
+ 
x 
x 
x 
+ 
x 
x 
++ 
+ 
x 
x 
++ 
x 
+ 
x 
x 
x 
x 
+ 
x 
6. Analytical rigour a. Sufficient data points to enable reliable statistical inference 
b. Shaping of intervention effect specified 
c. Analysis sufficiently rigorous/free from bias 
x 
x 
+ 
x 
x 
+ 
++ 
+ 
+ 
x 
x 
+ 
x 
x 
+ 
x 
x 
+ 
x 
x 
+ 
7. Managing bias in reporting/ethical 
considerations 
a. Free of selective outcome reporting 
b. Limitations addressed 
c. Conclusions clear and justified 
d. Free of other bias 
e. Ethics issues addressed 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
a 
Applicability of quality criteria to each study design: + Criteria to be included in quality assessment for study design; ++ Mandatory criteria to be met quality assessment; x Criteria not to be 
applied in quality assessment for study design.  
b
 Study designs: RCT =randomised controlled trial; CBA =controlled before-after; CITS ¼ controlled interrupted time series; CS = cohort study; NCITS =non-controlled interrupted time series; 
NCBA =non-controlled before-after; QUAL = qualitative.
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Table 2 -Decision matrix e mandatory criteria and minimum score for study type to be included in 
review.  
Study Design 
a
 Mandatory criteria 
b
 Minimum score 
RCT, cRCT 1A, 2A, 2B, and 3A 22 
CBA 1A, 2D, 3B and 3C 18 
CITS 1A, 3D and 6A 18 
NCITS 1A, 1B, 2C and 5D 22 
NCBA 1A, 1B, 2C and 5D 22 
Cohort  1A, 2E, 3G and 4C 18 
Qualitative 1A, 1E and 2F 16 
 
a
 Study Designs: RCT = randomised controlled trial; CBA =controlled before-after; CITS = controlled 
interrupted time series; cRCT =cluster-randomized controlled trial; NCITS = noncontrolled interrupted 
time series; NCBA =non-controlled before-after. 
 
b
 Scores applicable to each criteria: Yes (criterion met) =2 points; Unclear (unclear whether or not the 
criterion is met) =1 point; No (criterion not met) = 0 points. 
 
Adapted from Zingg W et al. Innovative tools for quality assessment: integrated quality criteria for 
review of multiple study designs (ICROMS). Public Health 2016;133:19-37. 
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Table  1- Antimicrobial stewardship program in children, including PICU and outcomes (2007-2017). 
Study 
author 
and 
reference 
Study design   Setting, number 
of subjects 
Country,  
study period 
 Aim (s) Interventions Summary of key findings 
 
 
 
 
 
Kreitmeyr 
et al (11) 
 
 
 
 
 
Non-controlled before-
and-after study 
 
 
 273 patients (pre-
intervention) and 
263 patients (post-
intervention) 
Four paediatric 
wards. Single centre 
 
 
 
Germany, 2014-
2015 
 
 
a) to assess the impact of 
specific ASP interventions on 
antibiotic consumption in 
general paediatric wards.  
 
b) to evaluate the effectiveness 
of interventions in improving 
guideline adherence, antibiotic 
selection, dosing accuracy, and 
reduction of overall and 
specifically targeted antibiotics 
(cephalosporins and 
fluoroquinolones). 
 
 
 
 
Guidelines, antibiotic 
restriction policy, 
audit and feedback 
 
• Guideline adherence for community-acquired 
pneumonia improved from 39.5% to 93.5% 
• Dose accuracy improved from 78.8%  to 97.6% 
• Decrease of cephalosporins and 
fluoroquinolones by 35.5% and 59.9% (p<0.001), 
respectively 
• Decrease of days-of-therapy and length-of-
therapy by 10.5% (p<0.001) and 7.7% ( p=0.02), 
respectively. 
 
 
 
 
 
 
Hersh et al 
(12)   
 
 
 
 
Controlled interrupted 
time series 
 
 
31 freestanding 
children’s hospitals 
affiliated with the 
Children’s Hospital 
Association. General 
wards and PICUs. 
 
 
 
USA, 2004-2012 
 
 
a) to compare antibiotic 
prescribing rates in a group of 
paediatric hospitals with 
formalized ASPs (ASP+) (9 
hospitals) to a group of 
concurrent control hospitals 
without formalized stewardship 
programs (ASP -) (22 hospitals). 
 
ASP: elements of 
prospective audit and 
feedback, formulary 
restriction, and use of 
clinical guidelines. 
Intervention not fully 
described 
 
• Average monthly decline in days of therapy/1000 
patient-days of 5.7% ( in 8 of 9 of ASP + hospitals) 
• Average monthly decline of 8.2% for selected 
antibiotics (vancomycin, carbapenems and 
linezolid) 
•Decrease of all antibiotic use in ASP + compared 
with ASP – ( p=0.04) 
 
 
 
 
 
Murni et 
al (13)   
 
 
 
Controlled before-and-
after study 
 
 
2646 children aged 
1 month to less than 
18 years. General 
wards and PICU. 
Single centre 
 
 
 
Indonesia, 
2010-2013 
 
 
a) to implement a multi-
faceted infection control and 
antibiotic stewardship 
programme and evaluate its 
effectiveness on healthcare-
associated infections, antibiotic 
use, and hand hygiene 
compliance. 
 
 
 
Guidelines, training 
of human resources, 
audit and feedback, 
hand hygiene 
compliance 
 
• Decrease of HAI in PICU from 45.1 % to 17.1% 
[RR = 0.37 (0.28-0.51)] 
• Decrease of patients exposed to inappropriate 
or incorrect antibiotics from 55.6% to 33% [RR = 
0.64 (0.52-0.79)] 
• Increase of hand hygiene compliance from 
11.7% to 62.4 %, (p<0.001)  
 
 
 
 
Seah et al 
(14)  
 
 
 
Non-controlled 
interrupted time series 
 
 
 
 
830-bed tertiary 
care hospital. 
Paediatric and 
obstetric wards. 
Single centre. 
 
 
Singapore, 
2009-2013 
 
 
 
 
a) to evaluate the impact of 
implementing a prospective 
audit and feedback ASP on 
appropriate utilization of 
carbapenems. 
 
 
 
 
Guidelines, audit and 
feedback 
 
• Decrease in DDDs per 100 patient-days 
by 55.6% from 0.9 to 0.4 (p=0.013)  
• Decrease of DOTs per 100 patient-days by 
46.7% from 1.5 to 0.8 (p=0.06)  
• No changes in prescription rates 
• Paediatric carbapenems utilization cost 
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  decrease to a mean of $149 post-ASP (p=0.01)  
 
 
 
Newland 
et al (15)   
 
 
Controlled interrupted 
time series 
 
 
317-bed tertiary 
care children’s 
hospital. PICU, NICU 
and general wards. 
Single centre. 
 
 
 
USA, 2004-2010 
 
 
 
 
a) to demonstrate the impact 
of a prospective audit and 
feedback ASP on antimicrobial 
use. 
 
 
Audit and feedback 
 
• Compliance of 92% with ASP recommendations 
• Monthly decline in DOT and LOT for all 
antibiotics by 7% (p=0.045) and 8% (p=0.045), 
respectively 
• Monthly decline DOT and LOT for selected 
antibiotics by 17% (p<0.001) and 18%  (p<0.001) 
 
 
 
Sick et al 
(16)  
 
 
 
Cohort study 
 
 
188 bed paediatric 
hospital. General 
wards. PICU 
excluded 
Single centre. 
 
 
 
USA, 2005–
2011 
 
a) to evaluate an internet-
based pre-approval ASP for 
sustained reduction in 
antimicrobial prescribing and 
resulting cost savings. 
 
 
Pre-authorisation, 
antibiotic restriction 
policy. 
 
 
• Decrease of numbers of unrestricted doses but 
no decrease of numbers of restricted doses 
•  Preapproval of ASP saved $103,787 (95% CI, 
$98,583–$109,172) per year, or $14,156 (95% CI, 
$13,446–$14,890) per 1,000 patient-days. 
• Average annual approval rate of 91.5% for 
restricted antibiotics 
 
 
 
 
Newman 
et al (17)  
 
 
 
 
Non-controlled before-
and-after study 
 
Paediatric wards. 
530 children pre-
intervention and 
503 children post-
intervention. Single 
centre. 
 
 
 
 
 
USA, 2007-2009 
 
 
a) to describe the impact of a 
clinical practice gguideline 
(CPG) on antibiotic 
management of children with 
community-acquired 
pneumonia. 
 
 
 
 
Guidelines, audit and 
feedback 
 
• Increase of ampicillin use by 34% after 
guideline implementation 
• Most commonly antibiotic prescribed for CAP 
(Pre-CPG): Ceftriaxone(72%); Most commonly 
antibiotic prescribed for CAP (Post-CPG):  - 
Ampicillin( 63%) 
• Change in antibiotic prescription at discharge: 
increase of amoxicillin (p<0.001); decrease of 
cefdinir and co-amoxiclav (p<0.001)  
• Overall treatment failure was infrequent (1.5% 
vs. 1%) 
 
 
 
Di 
Pentima 
et al (18)  
 
 
 
 
Non-controlled 
interrupted time series 
 
 
180-bed tertiary 
care academic 
paediatric hospital. 
PICU, NICU and 
general wards 
included. Single 
centre. 
 
 
 
 
USA, 2003-2007 
 
 
a) to prospectively evaluate 
the effect of a comprehensive 
ASP on antimicrobial use, 
physician interventions, 
patient outcomes, and rates of 
antimicrobial resistance. 
 
 
Antibiotic restriction 
policy, pre-
authorisation, audit 
and feedback 
 
• Decline of targeted antibiotics from 1250 to 
988 doses administered per 1000 patient-days 
per year (p<0.001) 
 
• No changes of resistance to Pseudomonas 
aeruginosa, Enterobacter cloacae, E.coli and 
Klebsiella pneumoniae during the study 
 
 
 
 
Di 
Pentima 
 
 
 
Non-controlled before-
 
180-bed tertiary 
care academic 
paediatric hospital. 
 
 
 
USA, 2004-2007 
 
a) to evaluate the impact of 
implementing an ASP on 
vancomycin use 
 
 
 
Guidelines, antibiotic 
 
• Decrease of vancomycin use from 378 doses 
administered/1000 patient-days to 255 doses 
administered/1000 patient-days (p<0.001) 
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et al (19)  and-after study 
  
PICU, NICU and 
general wards 
included. Single 
centre. 
 
 restriction policy, 
audit and feedback 
 
• No increased use of other antibiotics with 
similar antimicrobial activity of vancomycin 
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Figure 1- Study selection- Systematic review on the role of antimicrobial stewardship programmes in children 
(2007-2017) 
 
  
2203 articles reporting on adult 
populations excluded 
2509 articles identified 
305 titles and abstracts 
298 articles excluded: 
• Studies on adult populations (64) 
• Non-acute care (40)   
• Reviews, letters, notes, conference 
abstracts and opinion articles (117) 
• Not related to outcome measures (77) 
2 additional articles identified from 
references articles.   
 9 articles included in the final 
analysis 
7 full text 
articles  
                    306 articles on 
paediatric populations 
1 duplicate article excluded 
